BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M

Executive Summary

• BioVaxys Technology Corp. upsized its non‑brokered private placement, now offering up to 11,764,705 units at $0.17 per unit for gross proceeds of up to $2 million.
• Each unit consists of one common share and one warrant to purchase an additional share at $0.40 exercisable for 24 months.
• Proceeds are earmarked for organic pipeline growth—including licensing, pre‑clinical DPX supply, food‑allergy program initiation, patent activities, and data analysis for out‑licensing opportunities.

Key Details

• Offering Size: Minimum 10,588,235 units → $1.8 M; Maximum 11,764,705 units → up to $2 M.
• Issue Price: $0.17 per unit.
• Unit Composition: 1 common share + 1 common share purchase warrant (exercise price $0.40, 24‑month term).
• Closing Date: On or before 2025‑11‑10 (or earlier/later as determined by the Company).
• Regulatory Conditions: Subject to receipt of all required regulatory approvals, including acceptance by the Canadian Securities Exchange (CSE).
• Use of Proceeds:
  1. Pursue licensing opportunities and research collaborations with DPX platform.
  2. Identify/produce GLP‑grade preclinical supply of DPX for peanut allergy vaccine program and expand DPX formulations into mRNA & neoantigens.
  3. Initiate DPX food‑allergy program at McMaster University (preclinical proof‑of‑concept for peanut antigen prophylaxis).
  4. File new patents and maintain annuity payments on existing patents.
  5. Complete immunological data analysis from MVP‑S Phase 1 studies to prepare assets for out‑licensing in additional tumor types.
• Finder’s Fees: Company may pay eligible finders who introduce subscribers.
• Exemption Basis: Offered under the Listed Issuer Financing Exemption (Part 5A of NI 45‑106) – no hold period required.
• Documentation: Amended and restated offering document dated 2025‑10‑28 available on SEDAR+ and company website.

Notable Quotes

“The additional capital will accelerate our pipeline development, enabling us to advance multiple DPX‑based programs and strengthen our position as a go‑to partner for targeted immunotherapies,” – James Passin, Chief Executive Officer.